Search results
Showing 751 to 800 of 8137 results
Guidance, advice and support for delivering quality, safety and efficiency in the use of medicines
Organisations that can use the NICE electronic and print content framework
Dr Ravinder Claire outlines recent progress towards greater use of real-world evidence in regulatory decision-making. He also considers the implications and opportunities for NICE and our stakeholders.
Part of NICEimpact maternity and neonatal care Previous: Introduction Next: Maternity and mental health In May 2018 we
Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)
Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.
Delirium: prevention, diagnosis and management in hospital and long-term care (CG103)
This guideline covers diagnosing and treating delirium in people aged 18 and over in hospital and in long-term residential care or a nursing home. It also covers identifying people at risk of developing delirium in these settings and preventing onset. It aims to improve diagnosis of delirium and reduce hospital stays and complications.
Ambu aScope 4 Broncho for routine diagnostic and therapeutic bronchoscopy (MIB314)
NICE has developed a medtech innovation briefing (MIB) on Ambu aScope 4 Broncho for routine diagnostic and therapeutic bronchoscopy .
Adults with depression who want to stop taking antidepressants should have the dose of their medication reduced in stages to reduce the likelihood and severity of withdrawal symptoms, NICE has said.
Trabeculectomy with a biodegradable collagen matrix implant for glaucoma (IPG750)
Evidence-based recommendations on trabeculectomy with a biodegradable collagen matrix implant for glaucoma. This involves cutting a small flap in the white of the eye and putting a patch over the flap to help healing and prevent scarring. Fluid slowly drains out of the flap and the patch dissolves over time. The aim is to reduce pressure in the eye and slow or stop damage to sight.
View recommendations for IPG750Show all sections
After discussion with Paion AG, NICE is unable to make a recommendation on angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock. The company did not make an evidence submission because of uncertainty about the number of people who would be eligible for treatment. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA859
Tobacco: preventing uptake, promoting quitting and treating dependence (NG209)
This guideline covers support to stop smoking for everyone aged 12 and over, and help to reduce people's harm from smoking if they are not ready to stop in one go . It also covers ways to prevent children, young people and young adults aged 24 and under from taking up smoking. The guideline brings together and updates all NICE's previous guidelines on using tobacco, including smokeless tobacco . It covers nicotine replacement therapy and e-cigarettes to help people stop smoking or reduce their harm from smoking. It does not cover using tobacco products such as ‘heat not burn’ tobacco.
Show all sections
Sections for NG209
- Overview
- Recommendations on preventing uptake
- Recommendations on promoting quitting
- Recommendations on treating tobacco dependence
- Recommendations on treating tobacco dependence in pregnant women
- Recommendations on policy, commissioning and training
- Terms used in this guideline
- Recommendations for research
This guideline covers support for disabled children and young people with severe complex needs, from birth to 25 years. It aims to encourage education, health and social care services to work together and provide more coordinated support to children and young people, and their families and carers.
Show all sections
Sections for NG213
- Overview
- Recommendations on support for all disabled children and young people with severe complex needs
- Recommendations on specialist support for disabled children and young people with particular needs
- Recommendations on service organisation, integration and commissioning
- Terms used in this guideline
- Recommendations for research
- Rationale and impact for recommendations on supporting all disabled children and young people with severe complex needs
- Rationale and impact for recommendations on specialist support for disabled children and young people with particular needs
New evidence on the safety of statins means more people could benefit from them, new NICE draft guidance says.
Our experts can review the use of NICE content in your products or services. We can check you are using our content accurately and the context is...
MRI-based technologies for assessing non-alcoholic fatty liver disease (DG50)
Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease
What is OpenAthens? It is an authentication system that acts as a key to unlock access to resources for eligible health and care staff. An NHS...
Transcutaneous electrical stimulation of the trigeminal nerve for ADHD (IPG748)
Evidence-based recommendations on transcutaneous electrical stimulation of the trigeminal nerve for ADHD. This involves a single-use electrode patch stuck to the forehead, which sends small electrical pulses through the skin during sleep.
View recommendations for IPG748Show all sections
Laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease (IPG749)
Evidence-based recommendations on laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease. This involves placing a ring of beads outside of the food pipe, just above the stomach. Magnets inside the beads hold them together to keep the food pipe closed but are weak enough to move apart to allow food or liquid to be swallowed. The aim is to prevent acid reflux.
View recommendations for IPG749Show all sections
Evidence-based recommendations on nivolumab (Opdivo) with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in adults.
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (TA858)
Evidence-based recommendations on lenvatinib (Kisplyx) with pembrolizumab (Keytruda) for untreated advanced renal cell carcinoma in adults.
PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis (MIB313)
NICE has developed a medtech innovation briefing (MIB) on PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis .
Around 105,000 people with type 1 diabetes could benefit from NICE’s draft recommendation
This quality standard covers managing diabetes and its complications in women who are planning a pregnancy or are already pregnant. It includes care for women with pre-existing diabetes before and during pregnancy, and diagnosis and management of gestational diabetes. It describes high-quality care in priority areas for improvement.
View quality statements for QS109Show all sections
Sections for QS109
- Quality statements
- Quality statement 1: Preconception planning
- Quality statement 2: Joint diabetes and antenatal team care
- Quality statement 3: Continuous glucose monitoring
- Quality statement 4: Postnatal testing and referral
- Quality statement 5: Annual HbA1c tests
- Update information
- About this quality standard
This quality standard covers assessing, diagnosing and managing chronic heart failure in adults (aged 18 and over). It describes high-quality care in priority areas for improvement. Statements cover adults with chronic heart failure with reduced ejection fraction and adults with chronic heart failure with preserved ejection fraction, unless otherwise stated.
View quality statements for QS9Show all sections
Sections for QS9
- Quality statements
- Quality statement 1: N-terminal pro-B-type natriuretic peptide measurement
- Quality statement 2: Specialist assessment
- Quality statement 3: Medication for chronic heart failure with reduced ejection fraction
- Quality statement 4: Review after changes in medication
- Quality statement 5: Review of people with chronic heart failure
- Quality statement 6: Cardiac rehabilitation
- Update information
This indicator covers the rate of people admitted with a primary diagnosis of hip fracture per 100,000 population. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG24
This indicator covers the proportion of people in the National Hip Fracture Database who have received all 8 care processes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG23
Hip fracture: surgery on the day or day after admission (IND14)
This indicator covers the proportion of people with hip fracture, who receive surgery on the day of, or the day after, admission. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG21
Hip fracture: formal hip fracture programme from admission (IND13)
This indicator covers the proportion of people with hip fracture, who receive a formal hip fracture programme from admission. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG20
Recommendation ID TA854/01 Question Further research is recommended to help address remaining clinical and cost-effectiveness uncertainties
Recommendation ID NG230/04 Question Duration of thyroid stimulating hormone suppression: For people with differentiated thyroid cancer
Recommendation ID NG230/07 Question Imaging for further staging: For people with differentiated thyroid cancer who have initial ultrasound
Recommendation ID NG230/03 Question Active surveillance compared with surgery: For people with stage 1 differentiated thyroid cancer, what
Recommendation ID NG230/06 Question Thyroid peroxidase antibody testing: For people with indeterminate cytopathology, what is the clinical
Recommendation ID NG230/01 Question Molecular tests: In fine-needle aspiration cytology (FNAC) samples that are adequate but cannot differentiate
Recommendation ID NG230/02 Question Duration of follow up: What is the clinical and cost effectiveness for different durations of follow
Recommendation ID MTG75/01 Question Given the limited evidence available, the original guidance committee noted that it would be beneficial
Postpartum haemorrhage: What is the most effective treatment for primary postpartum haemorrhage?
Recommendation ID CG190/05 Question Postpartum haemorrhage: What is the most effective treatment for primary postpartum haemorrhage?
This quality standard covers diagnosing and managing hip fracture in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS16Show all sections
Sections for QS16
- Quality statements
- Quality statement 1: Multidisciplinary management
- Quality statement 2: Timing and expertise for surgery
- Quality statement 3: Intracapsular fracture
- Quality statement 4: Trochanteric fracture
- Quality statement 5: Subtrochanteric fracture
- Quality statement 6: Rehabilitation after surgery
- Update information
Recommendation ID CG190/04 Question Education about the latent first stage of labour: Does enhanced education specifically about the latent
Recommendation ID CG190/03 Question Long‑term consequences of planning birth in different settings: What are the long‑term consequences
Recommendation ID NG230/05 Question Radioactive iodine: What is the clinical and cost effectiveness of RAI after total or completion thyroidectomy
Recommendation ID NG230/08 Question External beam radiotherapy compared with usual care: What is the clinical and cost effectiveness of
This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.
Percutaneous image-guided cryoablation of peripheral neuroma for chronic pain (IPG747)
Evidence-based recommendations on percutaneous image-guided cryoablation of peripheral neuroma for chronic pain. This involves using a needle-like probe to freeze and destroy small parts of nerves in neuromas to stop the pain signals.
View recommendations for IPG747Show all sections
Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderately to severely active ulcerative colitis in adults.
NICE has withdrawn this guidance. Takeda will stop marketing mobocertinib (Exkivity) and its marketing authorisation has been withdrawn. Healthcare professionals should discuss alternative treatment options with people currently having mobocertinib.
Tributes paid following the death of founding NICE chairman Professor Sir Mike Rawlins
As founding chairman of NICE, Sir Mike led NICE from 1999 to 2013, through its early formative years to its current position as a world leader in health and social care guidance and medicine evaluation.
NICE recommends a weekly injection for treating growth failure in children
This recommendation comes from a pilot to develop simpler, faster evaluations for the appraisal of some treatments.
Who is eligible for an OpenAthens account? NHS OpenAthens accounts are available to all NHS and public health staff, and many other health and social
NICE recommends Enhertu for more people with advanced breast cancer
Hundreds more people eligible for breast cancer drug Enhertu as NICE recommends it for earlier stage disease, in final draft guidance.